IDEA #30GV60 Gold Nanoparticles Modified with Cleavable Peptide Sequences for Disease Detection. 24A0027

Key Words: peptide, disease detection assay platform, biosensing, nanoparticles, optical detection The global market for infectious disease diagnostics is rapidly expanding, driven by the ongoing need for disease testing and the emergence of new pathogens. The diagnostic market is valued at approximately $20 billion and is projected to grow at 5-7% annually. This technology bridges the gap between point-of-care testing, which facilitates rapid monitoring in resource-limited settings with low sensitivity, and clinical laboratory-based testing, which provides the sensitivity required for early diagnoses but requires highly skilled technicians and complex instrumentation. This ability to provide clinical laboratory-level sensitivity, with the speed and broad applicability of point-of-care detection would be a remarkable improvement in clinical testing. In addition to good product-market fit, this technology would provide people and communities of all income groups and ethnicities access to this critical resource.